Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James L Riley

Showing results (91-100 of 127) with videos related to

Pageof 13
Sort By:
JCI Insight|September 20, 2016
Lack of immunoediting in murine pancreatic cancer reversed with neoantigenRebecca A Evans, Mark S Diamond, Andrew J Rech, et al.
The Journal of Experimental Medicine|May 5, 2026
Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levelsMeidi Gu, Kaitlin A Read, Vipin Bhardwaj, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2014
Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumorsEdmund K Moon, Liang-Chuan Wang, Douglas V Dolfi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 21, 2023
Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cellsMegan M Wyatt, Logan W Huff, Michelle H Nelson, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2009
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domainsCarmine Carpenito, Michael C Milone, Raffit Hassan, et al.
Blood|August 4, 2016
miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potencyYunjie Lu, Keli L Hippen, Amanda L Lemire, et al.
Science Translational Medicine|December 3, 2011
The PDL1-PD1 axis converts human TH1 cells into regulatory T cellsShoba Amarnath, Courtney W Mangus, James C M Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patientsKatia Schlienger, Christina S Chu, Edward Y Woo, et al.
Cell Reports|April 19, 2018
Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient EnvironmentsChristopher Ecker, Lili Guo, Stefana Voicu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2008
CD28 costimulation is essential for human T regulatory expansion and functionTatiana N Golovina, Tatiana Mikheeva, Megan M Suhoski, et al.
Pageof 13

Showing results (91-100 of 127) with videos related to

Sort By:
Pageof 13
JCI Insight|September 20, 2016
Lack of immunoediting in murine pancreatic cancer reversed with neoantigenRebecca A Evans, Mark S Diamond, Andrew J Rech, et al.
The Journal of Experimental Medicine|May 5, 2026
Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levelsMeidi Gu, Kaitlin A Read, Vipin Bhardwaj, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2014
Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumorsEdmund K Moon, Liang-Chuan Wang, Douglas V Dolfi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 21, 2023
Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cellsMegan M Wyatt, Logan W Huff, Michelle H Nelson, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2009
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domainsCarmine Carpenito, Michael C Milone, Raffit Hassan, et al.
Blood|August 4, 2016
miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potencyYunjie Lu, Keli L Hippen, Amanda L Lemire, et al.
Science Translational Medicine|December 3, 2011
The PDL1-PD1 axis converts human TH1 cells into regulatory T cellsShoba Amarnath, Courtney W Mangus, James C M Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patientsKatia Schlienger, Christina S Chu, Edward Y Woo, et al.
Cell Reports|April 19, 2018
Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient EnvironmentsChristopher Ecker, Lili Guo, Stefana Voicu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2008
CD28 costimulation is essential for human T regulatory expansion and functionTatiana N Golovina, Tatiana Mikheeva, Megan M Suhoski, et al.
Pageof 13